Cancer Testis Antigens: A Novel Target in Lung Cancer

REFERENCES

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: A Cancer J Clin. 2005;55(2):74–108.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA: A Cancer J Clin. 2009; 59(4):225–249.
   PubMed Web of Science ®Google Scholar
• Hsu H-C, Lee Y-L, Cheng T-S, et al. Characterization of two non-testis-specific CABYR variants that bind to GSK3β with a proline-rich extensin-like domain. Biochemical and Biophysical Research Communications. 2005;329(3):1108–1117.
   PubMedGoogle Scholar
• Scanlan M, Simpson A, Old L. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4:1.
   PubMedGoogle Scholar
• Scanlan MJ, Gure AO, Jungbluth AA, et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002;188(1):22–32.
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643–1647.
   PubMed Web of Science ®Google Scholar
• Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 1995;2(2):167–175.
   PubMed Web of Science ®Google Scholar
• Backer O, Arden KC, Boretti M, et al. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res. 1999;59:3157–3165.
   PubMed Web of Science ®Google Scholar
• Old LJ, Chen Y-T. New paths in human cancer serology. J Exp Med. 1998;187(8):1163–1167.
   PubMed Web of Science ®Google Scholar
• Simpson AJG, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615–625.
   PubMed Web of Science ®Google Scholar
• Ross MT, Grafham DV, Coffey AJ, et al. The DNA sequence of the human X chromosome. Nature. 2005;434(7031):325–337.
   PubMed Web of Science ®Google Scholar
• Caballero OL, Chen Y-T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009;100(11):2014–2021.
   PubMed Web of Science ®Google Scholar
• Chari R, Lonergan K, Ng R, et al. Effect of active smoking on the human bronchial epithelium transcriptome. BMC Genomics. 2007;8(1):297.
   PubMedGoogle Scholar
• Westbrook V, Schoppee P, Diekman A, et al. Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines. Clin Cancer Res. 2004;10(1):101–112.
   PubMedGoogle Scholar
• Fiszer D, Kurpisz M. Major histocompatibility complex expression on human, male germ cells: a review. Am J Reprod Immunol. 1998;40(3):172–176.
   PubMedGoogle Scholar
• Tung KSK, Teusher C. Mechanisms of autoimmune disease in the testis and ovary. Hum Reprod Update. 1995;1(1):35–50.
   PubMedGoogle Scholar
• Fratta E, Coral S, Covre A, The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 2011;5(2):164–182.
   PubMed Web of Science ®Google Scholar
• Laduron S, Deplus R, Zhou S, MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res. 2004;32(14):4340–4350.
   PubMedGoogle Scholar
• Thaete C, Brett D, Monaghan P, Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus. Hum Mol Gen. 1999;8(4):585–591.
   PubMedGoogle Scholar
• Herold A, Suyama M, Rodrigues JP, TAP (NXF1) belongs to a multigene family of putative RNA export factors with a conserved modular architecture. Mol Cell Biol. 2000;20(23):8996–9008.
   PubMedGoogle Scholar
• Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends in Genetics. 2000;16(4):168–174.
   PubMed Web of Science ®Google Scholar
• Kimmins S, Sassone-Corsi P. Chromatin remodelling and epigenetic features of germ cells. Nature. 2005;434(7033):583–589.
   PubMed Web of Science ®Google Scholar
• Aprelikova O, Pandolfi S, Tackett S, Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. Cancer Res. 2009;69(2):616–624.
   PubMed Web of Science ®Google Scholar
• Peikert T, Specks U, Farver C, Melanoma antigen A4 Is expressed in non–small cell lung cancers and promotes apoptosis. Cancer Res. 2006;66(9):4693–4700.
   PubMedGoogle Scholar
• Sakurai T, Itoh K, Higashitsuji H, A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. J Biol Chem. 2004;279(15):15505–15514.
   PubMedGoogle Scholar
• Nagao T, Higashitsuji H, Nonoguchi K, MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem. 2003;278(12):10668–10674.
   PubMed Web of Science ®Google Scholar
• Park J, Kong G, Lee S. hMAGE-A1 overexpression reduces TNF-alpha cytotoxicity in ME-180 cells. Mol Cells. 2002;14(1):122–129.
   PubMedGoogle Scholar
• Duan Z, Duan Y, Lamendola DE, Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res. 2003;9(7):2778–2785.
   PubMedGoogle Scholar
• Glynn SA, Gammell P, Heenan M, A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin. Br J Cancer. 2004;91(10):1800–1807.
   PubMedGoogle Scholar
• Bertram J, Palfner K, Hiddemann W, Kneba M. Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression. Anticancer Drugs. 1998;9(4):311–317.
   PubMed Web of Science ®Google Scholar
• Cilensek ZM, Yehiely F, Kular RK, Deiss LP. A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, interferon-g, taxol and g-irradiation. Cancer Biol Ther. 2002;1(4):372–379.
   Google Scholar
• Lee LWR, Wang X, Mixon A, NY-ESO-1 may be a potential target for lung cancer immunotherapy. Cancer J Sci Am. 1999;5(1):20–25.
   PubMed Web of Science ®Google Scholar
• Juretic A, Sarcevic B, Separovic V, Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat Med J. 2006;47(1):32–41.
   PubMedGoogle Scholar
• Cho H, Caballero OL, Gnjatic S, Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). Cancer Immun. 2006;6:12.
   PubMedGoogle Scholar
• Sugita Y, Wada H, Fujita S, NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res. 2004;64(6):2199–2204.
   PubMed Web of Science ®Google Scholar
• Theurillat J-P, Ingold F, Frei C, NY-ESO-1 protein expression in primary breast carcinoma and metastases—correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int J Cancer. 2007;120(11):2411–2417.
   PubMedGoogle Scholar
• Chiriva M, Mirandola L, Yu Y, Identification of new cancer/testis antigens in non-small cell lung cancer. J Immunol. 2011;165:16.
   Google Scholar
• Chiriva-Internati M. Sperm protein 17: clinical relevance of a cancer/testis antigen, from contraception to cancer immunotherapy, and beyond. Int Rev Immunol. 2011;30(2–3):138–149.
   PubMed Web of Science ®Google Scholar
• Kong M, Richardson RT, Widgren EE, O'Rand MG. Sequence and localization of the mouse sperm autoantigenic protein, Sp17. Biol Reprod. 1995;53(3):579–590.
   PubMedGoogle Scholar
• Lea I, Widgren E, O'Rand M. Association of sperm protein 17 with A-kinase anchoring protein 3 in flagella. Reprod Biol Endocrinol. 2004;2(1):57.
   PubMedGoogle Scholar
• Chiriva-Internati M, Wang Z, Salati E, Timmins P, Lim SH. Tumor vaccine for ovarian carcinoma targeting sperm protein 17. Cancer. 2002;94(9):2447–2453.
   PubMedGoogle Scholar
• Chiriva-Internati M, Grizzi F, Weidanz J, A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. J Immunol Methods. 2007;321(1–2):86–93.
   PubMedGoogle Scholar
• Kausar T. Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines. Int J Cancer. 2010;126(6):1494.
   PubMedGoogle Scholar
• Luo C, Xiao X, Liu D, CABYR Is a novel cancer-testis antigen in lung cancer. Clin Cancer Res. 2007;13(4):1288–1297.
   PubMedGoogle Scholar
• Naaby-Hansen S, Mandal A, Wolkowicz MJ, CABYR, a novel calcium-binding tyrosine phosphorylation-regulated fibrous sheath protein Involved in capacitation. Dev Biol. 2002;242(2):236–254.
   PubMedGoogle Scholar
• Almeida LG, Sakabe NJ, de Oliveira AR, CT database: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res. 2009;37(Suppl 1):D816–D819.
   Google Scholar
• Li Y-F, He W, Mandal A, CABYR binds to AKAP3 and ropporin in the human sperm fibrous sheath. Asian J Androl. 2011;13(2):266–274.
   PubMed Web of Science ®Google Scholar
• Li Y-F, He W, Jha KN, FSCB, a novel protein kinase A-phosphorylated calcium-binding protein, is a CABYR-binding partner involved in late steps of fibrous sheath biogenesis. J Biol Chem. 2007;282(47):34104–34119.
   PubMedGoogle Scholar
• Chiriva-Internati M, Cobos E, Silva DMD, Kast WM. Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun. 2008;8:8.
   PubMedGoogle Scholar
• Ollinger R, Alsheimer M, Benavente R. Mammalian protein SCP1 forms synaptonemal complex-like structures in the absence of meiotic chromosomes. Mol Biol Cell. 2005;16(1):212–217.
   PubMed Web of Science ®Google Scholar
• Güre AO, Wei IJ, Old LJ, Chen Y-T. The SSX gene family: characterization of 9 complete genes. Int J Cancer. 2002;101(5):448–453.
   PubMedGoogle Scholar
• De Smet C, Lurquin C, Leth B, DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol. 1999;19(11):7327–7335.
   PubMed Web of Science ®Google Scholar
• Oi S, Natsume A, Ito M, Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells. J Neurooncol. 2009;92(1):15–22.
   PubMed Web of Science ®Google Scholar
• Sigalotti L, Fratta E, Coral S, Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-Aza-2′-deoxycytidine. Cancer Res. 2004;64(24):9167–9171.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang Y, Ramsahoye B, Sp17 gene expression in myeloma cells is regulated by promoter methylation. Br J Cancer. 2004;81(8):1597–1603.
   Google Scholar
• Goelz S, Vogelstein B, Hamilton, Feinberg A. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science. 1985;228(4696):187–190.
   PubMed Web of Science ®Google Scholar
• Kang Y, Hong JA, Chen GA, Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. Oncogene. 2007;26(30):4394–4403.
   PubMedGoogle Scholar
• Howlader N, Noone A, Krapcho M, SEER cancer statistics review, 1975–2009. Bethesda, MD: National Cancer Institute; 2011.
   Google Scholar
• Gure AO, Chua R, Williamson B, Cancer-testis genes are coordinately expressed and are markers of poor outcome in non–small cell lung cancer. Clin Cancer Res. 2005;11(22):8055–8062.
   PubMedGoogle Scholar
• Tajima K, Obata Y, Tamaki H, Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer. 2003;42(1):23–33.
   PubMed Web of Science ®Google Scholar
• Yoshida N, Abe H, Ohkur T, Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol. 2006;28(5):1089–1098.
   PubMed Web of Science ®Google Scholar
• Grah J, Samija M, Juretic A, et al. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features. Coll Antropol. 2008;32(3):731–736.
   PubMedGoogle Scholar
• Melloni G, Ferreri A, Russo V, Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol Rep. 2004;12(1):145–151.
   PubMed Web of Science ®Google Scholar
• Shigematsu Y, Hanagiri T, Shiota H, Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. Lung Cancer. 2010;68(1):105–110.
   PubMed Web of Science ®Google Scholar
• Otavia LC, Yao-Tseng C. Innate immune regulation and cancer immunotherapy. New York: Springer; 2012. pp. 347–369.
   Google Scholar
• Konishi J, Toyooka S, Aoe M, et al. The relationship between NY-ESO-1 mRNA expression and clinicopathological features in non-small cell lung cancer. Oncol Rep. 2004;11(5):1063–1067.
   PubMed Web of Science ®Google Scholar
• Chen Y-T, Hsu M, Lee P, Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. Int J Cancer. 2009;124(12):2893–2898.
   PubMedGoogle Scholar
• Wang Y, Liang Z, Yuan YH, et al. Expression of multiple cancer-testis antigen genes in non-small cell lung cancer treated by chemotherapy prior surgery. Zhonghua Yi Xue Za Zhi. 2004;84(6):464–468.
   PubMedGoogle Scholar
• Ruault M vdBP, Brun ME, Boyle S, et al. New BAGE (B melanoma antigen) genes mapping to the juxtacentromeric regions of human chromosomes 13 and 21 have a cancer/testis expression profile. Eur J Hum Genet. 2002;10(12):833–840.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, LePage S, Elliott M, et al. Characterization of preexisting humoral immunity specific for two cancer-testis antigens overexpressed at the mRNA level in non-small cell lung cancer. Cancer Immun. 2006;6:3.
   PubMedGoogle Scholar
• Scagliotti GV, Longo M, Novello S. Non-small cell lung cancer in never smokers. Curr Opin Oncol. 2009;21(2):99–104 .
   PubMed Web of Science ®Google Scholar
• Lai Q, Zhang L, Sun Y. Association of XAGE-1 gene expression with clinical characteristics of lung cancer. Zhongguo Fei Ai Za Zhi. 2010;13(8):786–789.
   PubMedGoogle Scholar
• Fukuyama T, Hanagiri T, Takenoyama M, Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res. 2006;66(9):4922–4928.
   PubMedGoogle Scholar
• De Jong A, Buchli R, Robbins D. Characterization of sperm protein 17 in human somatic and neoplastic tissue. Cancer Lett. 2002;186(2):201–209.
   PubMedGoogle Scholar
• Chiriva-Internati M, Wang Z, Salati E, Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma. Scandinavian J Immunol. 2002;56(4):429–433.
   PubMedGoogle Scholar
• Groeper C, Gambazzi F, Zajac P, Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in nonsmall cell lung cancer. Int J Cancer. 2007;120(2):337–343.
   PubMedGoogle Scholar
• Wadle A, Kubuschok B, Imig J, Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int J Cancer. 2006;119(1):117–125.
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Arfsten J, Cao Y, Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood. 2007;109(3):1103–1112.
   PubMed Web of Science ®Google Scholar
• Jäger E, Stockert E, Zidianakis Z, Humoral immune responses of cancer patients against “Cancer-Testis” antigen NY-ESO-1: correlation with clinical events. Int J Cancer. 1999;84(5):506–510.
   PubMedGoogle Scholar
• Nakamura Y, Noguchi Y, Satoh E, Spontaneous remission of a non-small cell lung cancer possibly caused by anti-NY-ESO-1 immunity. Lung Cancer (Amsterdam, Netherlands). 2009;65(1):119–122.
   PubMedGoogle Scholar
• Atanackovic D, Altorki NK, Stockert E, Vaccine-Induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol. 2004;172(5):3289–3296.
   PubMed Web of Science ®Google Scholar
• Schumacher K, Haensch W, Röefzaad C, Schlag PM. Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinomas. Cancer Res. 2001;61(10):3932–3936.
   PubMed Web of Science ®Google Scholar
• Kim S, Lee S, Lee C, Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung. 2009;187(6):401–411.
   PubMed Web of Science ®Google Scholar
• Sienel W, Varwerk C, Linder A, Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardio-Thor Surg. 2004;25(1):131–134.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Zielinski M, Linder A, Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer. J Clin Oncol. 2007;25(18S):7554.
   Google Scholar
• GlaxoSmithKline. GSK1572932A antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with non-small cell lung cancer. NCT00480025. May 29, 2007.
   Google Scholar
• Sharma P, Altorki N. NY-ESO-1 plasmid DNA (pPJV7611) cancer vaccine. NCT00199849. August 21, 2007.
   Google Scholar
• Shiku H. Safety and immunogenicity of CHP-HER2 and CHP-NY-ESO-1 protein with OK-432 in antigen-expressing cancers. NCT00291473. March 2, 2009.
   Google Scholar